CPS1 and ovarian cancer: The present study observed for the first time a significantly decreased expression of CPS1 in the NCI/ADR-RES paclitaxel-resistant ovarian cancer cells in vitro and had the same effect also in the NCI/ADR-RES-xenografted mouse model in vivo after taxane treatment.